A ligand-independent peptide inhibitor, GF9, targeting the TREM-1 transmembrane domain and preventing the TREM-1/DAP12 interaction [237], has shown therapeutic efficacy in models of septic shock [37]. The gene discussed is TREM1; the disease is Shock.